A groundbreaking treatment for Type 2 diabetes may eliminate the need for insulin injections, offering new hope for patients. In a recent clinical trial, 86% of participants were able to stop using insulin after just a few weeks of therapy. The promising results were presented at the United European Gastroenterology’s annual conference.
The innovative treatment combines an existing drug, semaglutide, with a novel procedure known as re-cellularization via electroporation therapy (ReCET). Semaglutide, a medication used to mimic the effects of the GLP-1 hormone, helps regulate blood sugar levels in Type 2 diabetes patients. ReCET, performed via endoscopy, delivers small electrical pulses to the stomach’s mucosal lining, improving the body’s sensitivity to naturally-occurring insulin.
Continue reading… “New Therapy Offers Hope for Insulin-Free Type 2 Diabetes Treatment”